Mynzepli (Aflibercept)

Aflibercept is a fusion protein that binds VEGF‑A, VEGF‑B and placental growth factor with high affinity. By sequestering these ligands, it blocks activation of VEGF receptors on retinal endothelial cells, thereby inhibiting abnormal blood‑vessel growth and reducing vascular permeability in the eye.

The dosing regimen for Mynzepli is determined by the prescribing ophthalmologist based on the specific indication and patient response. Typically, the medication is administered as a single‑use intravitreal injection; the exact volume and frequency are set by the treating clinician.

Safety of aflibercept in pregnancy and lactation has not been established. The product is classified as pregnancy category unknown, and it is generally avoided in pregnant or nursing women unless the potential benefit justifies the potential risk.

To request Mynzepli, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Mynzepli (aflibercept) has a broader binding profile, targeting VEGF‑A, VEGF‑B and placental growth factor, whereas agents like ranibizumab bind only VEGF‑A. This broader spectrum may offer efficacy in cases resistant to other anti‑VEGF agents, but clinical choice depends on individual patient factors and physician judgment.

Mynzepli must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product has been removed from refrigeration for more than the specified time, it should not be used.

Mynzepli is given by a qualified ophthalmologist as a sterile intravitreal injection. The eye is prepared under aseptic conditions, and a small volume of the solution is injected into the vitreous cavity using a fine‑gauge needle. Post‑injection monitoring of intraocular pressure is recommended.

Serious adverse events include endophthalmitis (a severe eye infection), retinal detachment, and marked intraocular inflammation such as uveitis or vitritis. Systemic thromboembolic events have been reported rarely. Prompt medical attention is essential if any of these complications are suspected.

Mynzepli is contraindicated in patients with active ocular infection, recent intraocular surgery, or uncontrolled intraocular inflammation. Caution is advised for individuals with recent major cardiovascular events, those on systemic anticoagulation with high bleeding risk, and pregnant or nursing women due to unknown safety.